Repression of NHE1 expression by PPARγ activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8636-8644

  Kumar, Alan Prem ^a,b   Quake, Ai Li ^b   Chang, Michelle Ker Xing ^b   Zhou, Ting ^b,c   Lim, Kelly Swee Ying ^b,d   Singh, Rajeev ^c   Hewitt, Robert Edwin ^b,d   Salto Tellez, Manuel ^b   Pervaiz, Shazib ^b,c,e,f   Clément, Marie Véronique ^b,c  

^a Natl University Medical Institute   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f SINGAPORE MIT ALLIANCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; DAUNORUBICIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SMALL INTERFERING RNA; SODIUM PROTON EXCHANGE PROTEIN 1; TROGLITAZONE;

ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME REGULATION; ENZYME REPRESSION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TUMOR BIOPSY;

BLOTTING, WESTERN; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SODIUM-HYDROGEN ANTIPORTER; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 72249121406     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0219     Document Type: Article

References (45)

1. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839 (Pubitemid 126663112)
2. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803-812
3. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001;21:185-210.
4. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400: 378-382 (Pubitemid 29344205)
5. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-8811 (Pubitemid 28350570)
6. Veliceasa D, Schulze-Hoepfner FT, Volpert OV. PPARγ and agonists against cancer: rational design of complementation treatments. PPAR Res 2008;2008:945275.
7. Lapillonne H, Konopleva M, Tsao T, et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003;63:5926-5939 (Pubitemid 37187494)
8. Bonofiglio D, Aquila S, Catalano S, et al. Peroxisome proliferator-activated receptor-γ activates p53 gene promoter binding to the nuclear factor-κB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006;20:3083-3092 (Pubitemid 44833557)
9. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line. Oncogene 2003;22:5446-5450 (Pubitemid 37072199)
10. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-1608 (Pubitemid 30183431)
11. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor γ-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004;10:7022-7030 (Pubitemid 39383054)
12. Reshkin SJ, Bellizzi A, Caldeira S, et al. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation- associated phenotypes. FASEB J 2000;14:2185-2197 (Pubitemid 30843913)
13. + exchanger for tumor growth. Cancer Res 1989;49:205-211
14. + exchanger isoforms. Am J Physiol 1995;268:C283-96.
15. + exchangers. Physiol Rev 1997;77:51-74.
16. Bell SM, Schreiner CM, Schultheis PJ, et al. Targeted disruption of the murine Nhe1 locus induces ataxia, growth retardation, and seizures. Am J Physiol 1999; 276:C788-95.
17. Pouyssegur J, Franchi A, Pages G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 2001;240:186-96; discussion 196-198 (Pubitemid 33603787)
18. + exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. Cell Death Differ 2006;13:628-641
19. Kumar AP, Chang MKX, Fliegel L, Pervaiz S, Clement MV. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. Cell Death Differ 2007;14:1733-1746 (Pubitemid 47423641)
20. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813-819 (Pubitemid 3006325)
21. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-6650
22. + exchanger. Am J Physiol Renal Physiol 2003;284:F829-39.
23. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor γ ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 2004;279:8300-8315
24. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci U S A 1995;92: 8229-8233
25. Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARα ligands. Biochem Biophys Res Commun 2006;349:846-854
26. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000;60:1129-1138 (Pubitemid 30129556)
27. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 1998;19:49-53. (Pubitemid 28376825)
28. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352
29. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-1052 (Pubitemid 28417337)
30. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-241 (Pubitemid 27027193)
31. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004;279: 26991-27007
32. Cardone RA, Bellizzi A, Busco G, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007;18:1768-1780 (Pubitemid 46717558)
33. + exchanger gene during neuronal differentiation of embryonal carcinoma cells. J Biol Chem 1995;270:10420-10427
34. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 2000;278:C676-88. (Pubitemid 30211300)
35. + exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. Breast Cancer Res 2004;6:R616-28.
36. + exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003;9:2366-2373
37. Jurka J, Milosavljevic A. Reconstruction and analysis of human Alu genes. J Mol Evol 1991;32:105-121
38. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 1999;274:32048-32054 (Pubitemid 129503797)
39. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000;403:103-108 (Pubitemid 30038530)
40. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000;20: 4699-4707 (Pubitemid 30396117)
41. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev 2005;19: 453-461 (Pubitemid 40256277)
42. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005;437: 759-763 (Pubitemid 41486547)
43. Liu HF, Teng XC, Zheng JC, Chen G, Wang XW. Effect of NHE1 antisense gene transfection on the biological behavior of SGC-7901 human gastric carcinoma cells. World J Gastroenterol 2008;14:2162-2167
44. Girnun GD, Chen L, Silvaggi J, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008;14: 6478-6486
45. Girnun GD, Naseri E, Vafai SB, et al. Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 2007;11:395-406. (Pubitemid 46670076)